Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group

Tada T, Kurosaki M, Nakamura S, et al. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol [Internet]. 2021;93(11):6247-6256. https://doi.org/10.1002/jmv.27157

Publication Type:

Journal Article

Authors:

Tada, T; Kurosaki, M; Nakamura, S; et, al

Source:

J Med Virol, Volume 93, Issue 11, p.6247-6256 (2021)

URL:

https://doi.org/10.1002/jmv.27157

Keywords:

Decompensated Cirrhosis, hepatitis C virus, multicenter study, sofosbuvir and velpatasvir, Sustained virological response

Cited On:

Patients With Decompensated Cirrhosis

External Third-party Web Link:

https://pubmed.ncbi.nlm.nih.gov/34170517/

Export Citation:

RIS Format

Top